Can you give any commercial examples of how Polyplus-transfections technologies have been utilized?
Since 2001, our company has been marketing its transfection reagents worldwide for research use or protein and virus production. We also own the exclusive license for the use of the polymeric molecule polyethylenimine in transfection, which is widely used to produce recombinant proteins for therapeutic uses. The company also offers in vivo transfection reagents for delivering therapeutic nucleic acids, such as gene or siRNA, and cGMP-compliant reagents for clinical trials. Most advanced clinical trials using Polyplus delivery reagents include phase II bladder cancer therapeutics (Biocancell) and HIV immune therapy (Genetic Immunity). Q7: How do you think the growing nucleic acid therapeutics market will change during the next few years? The gene therapy market is moving towards maturity. Twenty years’ of experience seems reasonable for a radically new therapeutic approach. The more recent siRNA-based therapies benefit from this experience. Moreover, siRNA are much smaller than genes an
